Airways delivery of rifampicin microparticles for the treatment of tuberculosis.
A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis.
Suarez
S
S
School of Pharmacy, and Department of Pathology and Laboratory Animal Medicine, University of North Carolina at Chapel Hill, 27599, USA.
O'Hara
P
P
Kazantseva
M
M
Newcomer
C E
CE
Hopfer
R
R
McMurray
D N
DN
Hickey
A J
AJ
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006168:Guinea Pigs; D007327:Insufflation; D008297:Male; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy* / Q000473:pathology
D000904:Antibiotics, Antitubercular; D012293:Rifampin